Translational biology of osteosarcoma.
Nat Rev Cancer
; 14(11): 722-35, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25319867
ABSTRACT
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteossarcoma
/
Pesquisa Translacional Biomédica
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article